Shots:

• The P-III study assessing the efficacy and safety of Favipiravir + SSC vs SCC in 150 mild to moderate patients- randomized within a 48hour window of testing RT-PCR positive for COVID-19
• Results: P-III study the improvement in 1EPs with 28.6% faster viral clearance in the overall population as measured by the median time until cessation of oral shedding of the virus. 2EPs include 40% faster achievement of clinical cure- patients receiving clinical cure @day4 (69.8% vs 44.9%) median time to first-time use of oxygen in clinically deteriorated (5days vs 2days)
• on June 20- 2020- FabiFlu has received DCGI’s approval- making it the first oral approved medication in India for the treatment of mild to moderate COVID-19. Glenmark has initiated PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients

  Ref: Glenmark | Image: IndiaTVNews

Related News: Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to Treat Mild to Moderate COVID-19 in India